Favrille, Inc. (Nasdaq: FVRL)
Favrille targets on the immunotherapy for treatment of Non-Hodgkin's Lymphoma, currently its lead product is in Phase III trial.

Arpida Ltd. (SWX: ARPN.SW)
Arpida is a Swiss biopharmaceutical company focusing on the development of novel antibiotics for the treatment of severe bacterial infections. The most advance product is currently on its Phase III studies in the US and Europe.

Amphastar Pharmaceuticals, Inc.
Amphastar engages in the development, manufacture, and marketing of generic and specialty pharmaceutical products through its innnovative delivery systems. Sixty seven products are already on the market and more will be launched in the near future with high market potential.

Efficas, Inc.
Efficas is a neutraceutical company which differentiates itself with other health food companies by developing and manufacturing proprietary bioactives with clinically proven efficacy.

Bayhill Therapeutics Inc.
Bayhill is a DNA vaccine company targeting on turning off auto-immunity of several auto-immune diseases, such as multiple sclerosis, Type I diabetes and Lupus. The principle concept of modulating immunity has been successfully proved.

Altea Therapeutics Corp.
Altea develops drug delivery platform through skin patch for pain management and treatment of some chronic diseases.

PharmaEngine, Inc.
PharmaEngine in-licenses potential drug candidates for the treatment of cancer for the unmet market in Asia and Europe.

Bionime 
Bionime is a Taiwan company dedicates in the development, manufacture and marketing of innovative glucose meter. Its product has launched in several continents with high satisfaction from consumers.

TolerRx 
TolerRx develops monoclonal antibody harnessing on immune tolerance for treatment of . auto-immune diseases, including diabetes, multiple sclerosis, and rheumatoid arthritis.

Biokey 
Biokey applies it proprietary technology in reformulating existing drugs for better efficiency and safety.

New Medical (NMC)
Based in Taiwan, NMC develops Digital X-ray Retrofit systems for general radiography (DR) and digital mammography (DM) applications. NMC also teams up with strategic partners in developing HIFU (High Intensity Focused Ultrasound) systems for advanced image-guided therapy solutions.

Dynogen Pharmaceutical Inc.
Dynogen is a clinical stage pharmaceutical company developing more effective treatments for gastrointestinal (GI) and genitourinary (GU) disorders, such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD) and overactive bladder (OAB).

Disc Dynamics Inc. (DDI)
Based in Eden Prairie, MN, U.S.A, DDI was established to provide patients and physicians with a minimally invasive surgical alternative for treating low back pain.

Optimer Pharmaceuticals, Inc.
Founded in 1998, Optimer has headquarters located in San Diego and subsidiary, Optimer Biotechnology, Inc. in Taipei, Taiwan. Optimer is currently focused on discovering, developing, and commercializing innovative anti-infective products in the treatment of CDAD, the most common nosocomial diarrhea, and travelers' diarrhea.

Portola Pharmaceuticals, Inc.
Portola dedicates to development of novel therapeutics for acute and chronic cardiovascular and vascular disease. Its lead compound, PRT054021, is an oral Factor Xa inhibitor for the prevention of venous thromboembolism, stroke and myocardial infarction (MI). Second compound, PRT060128, is an oral and intravenous ADP receptor antagonist for patients with acute coronary syndrome,.

BioResource International Inc.
BioResource International (BRI) is a North Carolina based biotechnology company focused on the discovery and development of enzymes to enhance and protect animal and human health.

Neureus
Nereus Pharmaceuticals is an innovative drug discovery and development company pursuing untapped sources of chemical diversity through identifying drug candidates derived from marine microbes.

GlobeImmune
GlobeImmune is a biopharmaceutical company pioneering the discovery, development and manufacturing of potent, targeted molecular immunotherapies called Tarmogens for the treatment of infectious diseases and cancer.

Paratek Pharmaceuticals, Inc Inc.
Headquartered in Boston, MA, which is engaged in the discovery and commercialization of Tetracycline derivatives in the treatment of Multiple Antibiotic Resistance (MAR) bacteria infection and inflammatory diseases, such as Multiple Sclerosis.